Press release
A Deep Dive into Neuroblastoma Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034
Neuroblastoma
The growth of the neuroblastoma market is anticipated to be spurred by a heightened occurrence of children's cancer. Childhood cancer encompasses various types of cancer consistently affecting young adults and children, with typical targets being bones, blood, and the brain, requiring focussed treatment methods. The surging numbers of childhood cancer instances can be linked to enhancements in diagnostic techniques, informed awareness, environmental influences, genetic considerations, and progress in medical sciences. Neuroblastoma treatments offer precise remedies for childhood cancer, creating opportunities for more prompt and efficient methods of addressing it, thereby reducing the chances of it recurring and enhancing young patients' survival prospects. For instance, data from the American Cancer Society, a professional organization based in the US, projects that the number of cancer diagnoses among children below 15 years will reach approximately 9,620 in 2024, a significant rise from the 5,290 diagnosed cases in 2023. Consequently, this surge in incidents of childhood cancer is fuelling the expansion of the neuroblastoma market.
Get Your Neuroblastoma Market Report Here:
https://www.thebusinessresearchcompany.com/report/neuroblastoma--global-market-report
How will the growth rate of the neuroblastoma market shape industry trends by 2034?
In recent times, there has been a significant expansion in the neuroblastoma market. The market is anticipated to increase from $2.97 billion in 2024 to $3.15 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The growth pattern witnessed in the historical phase can be linked with an upsurge in neuroblastoma cases, an enhanced focus on research and development relating to pediatric neuroblastoma remedies, a rise in childhood cancer incidents, and increasing financial aid and backing from the government.
In the upcoming years, the neuroblastoma market size is predicted to experience robust growth, escalating to a value of $3.93 billion by 2029 at a compound annual growth rate of 5.7%. The substantial growth during the prediction period is ascribed to factors such as rising governmental funding, growing frequency of the disease, heightened emphasis on early diagnosis, escalating occurrences of genetic alterations, and an expanding comprehension and advancements in research. The forecast period is anticipated to see significant trends including drugs' development that target specific molecular pathways, breakthroughs in non-invasive imaging technologies, progress in gene-editing technologies, a zoomed focus on individualized treatments, and the creation of radiolabeled compounds.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
What trends are poised to drive the future success of the neuroblastoma market?
Pioneering companies in the neuroblastoma market are concentrating their efforts on the development of cutting-edge therapeutic approaches. These include the use of humanized anti-GD2 monoclonal antibodies, which are specifically intended to more effectively and safely target and treat cancer cells. Such an antibody is carefully designed to target the GD2 molecule on cancer cells with minimized immune rejection by integrating human elements. For example, Renaissance Pharma Ltd., a clinical-stage pharmaceutical firm based in the UK, revealed in August 2023 that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital. This antibody is tailored to treat newly diagnosed high-risk neuroblastoma, a rare and life-threatening paediatric cancer. As per the terms of the agreement, Renaissance now holds exclusive rights to develop, manufacture, and distribute Hu14.18 in critical global markets, such as the United States, Canada, Europe, China, Japan, and Turkey.
Which primary segments of the neuroblastoma market are driving growth and industry transformations?
The neuroblastoma market covered in this report is segmented -
1) By Product Types: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
Which geographical regions are pioneering growth in the neuroblastoma market?
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the influential players reshaping the neuroblastoma market landscape?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp
What Is Covered In The Neuroblastoma Global Market Report?
•Market Size Forecast: Examine the neuroblastoma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neuroblastoma market for a structured understanding.
•Key Players Overview: Analyze major players in the neuroblastoma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neuroblastoma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neuroblastoma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neuroblastoma market.
•Industry Challenges: Identify potential risks and obstacles affecting the neuroblastoma market.
•Competitive Landscape: Review strategic developments in the neuroblastoma market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release A Deep Dive into Neuroblastoma Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034 here
News-ID: 3945125 • Views: …
More Releases from The Business Research Company
Top Market Shifts Transforming the Quantum-Enhanced Predictive Genomics Market L …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Quantum-Enhanced Predictive Genomics Market Through 2025?
The market size for quantum-enhanced predictive genomics has experienced rapid expansion in the past few years. The market is projected to increase from $1.45 billion in 2024 to $1.95 billion in 2025, displaying a compound annual…
Increasing Demand For Minimally Invasive Aesthetic Procedures Fueling The Growth …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Poly-L-Lactic Acid (PLA) Thread Lift Market Through 2025?
In recent times, the market size of the poly-L-lactic acid (PLA) thread lift has expanded exponentially. This market is projected to increase from $1.28 billion in 2024 to $1.49 billion in 2025, with a…
2025-2034 Pharmerging Market Evolution: Disruptions, Innovations, and Untapped O …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pharmerging Market Through 2025?
The size of the pharmerging market has expanded significantly over the past few years. Its projected growth is slated to rise from $2042.23 billion in 2024 to $2259.20 billion in 2025, with a compound annual growth rate (CAGR)…
Soaring Demand Set to Propel Personalized Gene Therapy Treatment Market to $17.6 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Personalized Gene Therapy Treatment Market Through 2025?
In recent times, there has been substantial growth in the market size of personalized gene therapy treatment. Predictions suggest that the market will expand from a worth of $6.93 billion in 2024 to $8.38 billion…
More Releases for Neuroblastoma
Pediatric Neuroblastoma Market to Reach USD 2.6 Billion by 2034
Neuroblastoma is the most common extracranial solid tumor in children, typically affecting infants and young children under the age of five. Arising from immature nerve cells of the sympathetic nervous system, neuroblastoma accounts for approximately 8-10% of all childhood cancers but represents a significant share of pediatric oncology deaths due to its aggressive nature.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71561
Historically, treatment has relied on surgery, chemotherapy, and…
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
